Boniva is one of 155 small molecule programs targeting Bone Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
199 competitors in Lung Cancer
Imfinzi
Beyfortus
Boniva
Abraxane
Imjudo
Tecentriq
Alunbrig
Alecensa
Zepzelca
DATROWAY
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Regulatory
May 16, 2003
BONIVA
NDA NDA021455
Jan 6, 2006
BONIVA
NDA NDA021858
Sources
Details